Defense Research and Development Organization (DRDO) has decided to hand over the technology of drug 2DG, developed to treat patients of Covid 19, to pharma companies.
DRDO chief G Satheesh Reddy said that the manufacturing technology of 2DG, a drug developed by DRDO for the treatment of Covid-19, is being handed over to pharma companies so that this drug can reach more and more patients.
In a program organized in Indore, he said that 2 DG medicine has been developed in the laboratory of DRDO in Gwalior.He told that the technology for making this drug of Covid-19 has been handed over to seven-eight pharma companies.
The Drug Controller General of India (DCGI) has also given approval to these companies for its production.Reddy said that the Gwalior-based laboratory of DRDO has played an important role in the war against Kovid-19 and had also developed sanitizers, masks and PPE kits in a very short time during the heavy outbreak of the epidemic.
Specialties of 2 DG medicine
The specialty of 2DG is that it is very easy to use.It is available in a sachet which just needs to be dissolved and drunk.Scientists claim that with its use, recovery is quick in patients and they also need less oxygen.The dosage of 2DG medicine is five to seven days and it is drunk like glucose.